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860 The Journal of Thoracic and CardioBackground: Ischemic mitral regurgitation has been associated with diminished
survival compared with nonischemic mitral regurgitation. Conversion from mitral
valve replacement to valve repair has improved prognosis, but it is unclear whether
ischemic mitral regurgitation remains an independent predictor of outcome after
mitral valve repair.
Methods: Five hundred thirty-five patients undergoing mitral valve repair (primarily
rigid ring annuloplasty) with or without coronary bypass from 1993 through 2002
were reviewed retrospectively (ischemic mitral regurgitation, n 141; nonischemic
mitral regurgitation, n 394). A Cox proportional hazards model evaluated survival
as a function of 9 simultaneous covariates: ischemic versus nonischemic mitral
regurgitation, age, sex, number of medical comorbidities, ejection fraction, New
York Heart Association class, coronary disease, reoperation, and year of operation.
Results: According to univariable analysis, patients with ischemic mitral regurgi-
tation had greater age, higher comorbidity, lower ejection fraction, higher New York
Heart Association, and higher reoperation rate (all P  .001) compared with those
having nonischemic mitral regurgitation. Univariable 30-day mortality was as
follows: 4.3% for patients with ischemic mitral regurgitation versus 1.3% for
patients with nonischemic mitral regurgitation (P  .01). Unadjusted 5-year mor-
tality was as follows: 44%  5% for patients with ischemic mitral regurgitation
versus 16%  3% for patients with nonischemic mitral regurgitation (P  .001). In
the multivariable model, however, only the number of preoperative comorbidities
and advanced age were independent predictors of survival (P  .0001), whereas
ischemic mitral regurgitation, sex, ejection fraction, New York Heart Association
class, coronary disease, reoperation, and year of operation did not achieve signifi-
cance (all P  .19). After being adjusted for differences in all preoperative risk
factors, survival was not statistically different between ischemic mitral regurgitation
and nonischemic mitral regurgitation (P  .33).
Conclusions: With routine application of rigid ring annuloplasty, long-term patient
survival is more influenced by baseline patient characteristics and comorbidity than
by ischemic cause of mitral regurgitation per se. Future risk assessment and decision
making should be based on patient condition and should not be biased by ischemic
cause of mitral regurgitation.
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CDMitral regurgitation (MR) precipitatedby a myocardial infarction (ischemicMR [IMR]) significantly worsens theprognosis of patients with coronaryartery disease.1 Furthermore, surgicaltherapy for moderate-to-severe IMR
has been associated with diminished early and late survival
compared with nonischemic MR (NMR).2-7 As a result of
the perception that the worse prognosis after surgical inter-
vention for IMR is inherent to IMR itself, patients with IMR
have been more reluctantly referred for operation than pa-
tients with NMR.3,4
Although the results of mitral repair for IMR have im-
proved over the last 20 years,2,8 ongoing dissatisfaction with
outcomes has yielded many divergent approaches to IMR
repair, including undersized flexible ring annuloplasty,9 se-
lective valve replacement rather than repair,7 uniform
chordal sparing valve replacement,10 transection of second-
ary chordae,11 suture annuloplasty,12 posterior leaflet patch
extension,13 annular cinching,14 and papillary muscle
sling.15 For the last decade, however, the authors have
continued the consistent approach of routine rigid ring an-
nuloplasty and complete coronary revascularization for the
treatment of IMR. The present study was designed to ex-
amine the results of this management strategy and to assess
the influence of IMR as an independent predictor of survival
after mitral valve repair by multivariable regression model-
ing methods.
Methods
This series consisted of 535 consecutive patients undergoing mitral
valve repair for mitral regurgitation with or without coronary
artery bypass (CAB) by 2 surgeons at 2 institutions over a 9-year
period from January 1, 1993, to December 31, 2002. Patients
undergoing concurrent aortic, tricuspid, or pulmonic valvular pro-
cedures were excluded. Of these 535 patients, 141 had IMR, which
was defined as the combination of (1) prior myocardial infarction,
(2) 75% or greater stenosis of at least one coronary vessel, (3) a
corresponding regional wall motion abnormality, and (4) absence
of other mitral valve pathology, such as myxomatous prolapse or
primary leaflet fibrosis. The remaining 394 patients were consid-
ered to have NMR, with the distribution of mitral valve cause
being prolapse (n  290), pure annular dilatation (n  74),
endocarditis (n  20), or other (n  10).
Selected patients not requiring CAB (n  247) were ap-
proached with port-access technology,16 and the remainder re-
ceived median sternotomy. The final decision to repair the mitral
valve was based on observation of moderate-to-severe MR on the
prebypass transesophageal echocardiogram, together with preop-
erative echocardiography or ventriculography.17 The majority of
patients (524/535 [98%]) were managed with cardiopulmonary
bypass and cold potassium cardioplegia, and the remainder (11/
535 [2%]) underwent operations with hypothermic ventricular
fibrillation caused by previous surgical intervention or patent by-
pass grafts. Most (529/535 [99%]) underwent rigid ring annulo-
plasty (Carpentier Classic, Carpentier Physio [Edwards Life-
The Journal of Thoracisciences, Irvine, Calif], or Seguin [St Jude Medical, Inc, St Paul,
Minn] rings) sized according to the intertrigonal distance. In most
patients with IMR, the ring size was reduced by one size. Four
patients with large posterior aneurysms were treated with trans-
ventricular mitral repair.18 Two patients, deemed too small for a
24-mm ring, underwent suture annuloplasty. Annuloplasty rings
were inserted with interrupted horizontal mattress sutures but-
tressed with supra-annular pledgets, if needed, for additional
strength. Leaflet prolapse in the NMR group was managed with
various combinations of quadrangular or triangular resections,
leaflet sliding plasties, or polytetrafluoroethylene artificial chordal
replacements (Gore-Tex chordal replacement; W. L. Gore & As-
sociates, Inc, Newark, Del).19,20 All coronary vessels of 1.5 mm in
diameter or larger that were obstructed by 50% or greater were
bypassed. Most patients receiving coronary bypass grafting had at
least one internal thoracic artery inserted. Of patients with IMR
treated over this period but excluded from this series, 10 required
valve replacement: 1 for a ruptured large single posterior papillary
muscle, 7 for concomitant fibrosis or calcification of the anterior
leaflet, and 2 for prolapse caused by papillary muscle infarction.
After 1996, routine arrhythmia prophylaxis was used. Patients
were intravenously loaded with amiodarone starting at least 12
hours before surgical intervention20 or with procainamide intraop-
eratively. Oral therapy with amiodarone, sotalol, or other agents
was continued for at least 3 to 6 weeks postoperatively. Maze
operations or atrial ablations (n  27) were used only selectively
for patients with long-term preoperative atrial fibrillation.
Positive comorbidity of chronic lung disease was defined as
severe emphysema requiring daily pharmacologic therapy, preop-
erative renal insufficiency was defined as a serum creatinine level
of 1.5 mg/dL or greater, postoperative renal insufficiency was
defined as an increase in serum creatinine level of greater than 1.0
mg/dL, severe left ventricular dysfunction was an estimated ejec-
tion fraction of 0.35 or less, a stroke was a permanent neurologic
defect, and operative mortality was defined as death during hos-
pitalization or within 30 days of surgical intervention. Of the 535
patients, 99% had confirmation of clinical status or personal con-
tact by telephone in late 2002. Echocardiographic findings within
2 years of the follow-up date were documented. Maximal fol-
low-up was 9 years, and median follow-up was 4 years.
Baseline characteristics were reported as percentages for dis-
crete variables and compared by 2 tests; continuous variables
were described by median, 25th, and 75th percentiles, with differ-
ences assessed by Kruskal-Wallis tests. Cumulative survivals as a
function of time after the date of surgical intervention were gen-
erated by using the Kaplan-Meier method. The Cox proportional
hazards model was used to examine both univariable and multi-
variable relationships between baseline characteristics and mortal-
ity by using stepwise selection of candidate variables at an  value
of .05. The model evaluated long-term survival as a function of 9
simultaneous covariates: IMR versus NMR, age, sex, weighted
count of comorbidities (hypertension, smoking, diabetes, renal
insufficiency, pulmonary disease, peripheral vascular disease, and
cerebral vascular disease weighted on the basis of the parameter
estimates of these components in a separate Cox regression
model), ejection fraction (EF), New York Heart Association
(NYHA) class, coronary disease (CD), prior cardiac operation,
institution, and year of operation. The Cox model assumption of
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CDlinearity in the log hazard was tested for all continuous and ordinal
categoric variables, and they were transformed appropriately as
needed. None of the variables violated the assumption of propor-
tional hazards when tested in the Cox model. Potential colinearity
of independent variables was minimized by use of a total count of
comorbidities. Analysis was also repeated, including individual
comorbidities instead of the total number of comorbidities. Be-
cause of concerns that CD and impaired EF could act as surrogates
for IMR in the model, the analysis then was repeated with 8
variables plus CD and EF combined and then again with CD and
EF omitted. Additionally, adjusted survival curves were generated
to further evaluate the relationship between CD and cause, strati-
fying on cause in a CD-only subset population.
A propensity score analysis was performed to determine
whether the differences between the IMR and NMR groups re-
mained similar across different probabilities of the mitral valve
disease cause by using preoperative variables to create propensity
scores for the diagnosis of IMR versus NMR. After dividing all
patients into 5 equal strata on the basis of the propensity for
diagnosis of IMR, area under the survival curve was calculated for
each quintile, and differences between cause groups were tested
statistically. This study was approved by the Institutional Review
Boards of Centennial Hospital (Nashville, Tenn) and Duke Uni-
versity (Durham, NC).
Results
Ring size was significantly smaller for patients with IMR
TABLE 1. Preoperative patient characteristics
NMR IMR P value
N 394 141
Age (y) 59 (51-69) 69 (61-75) .001
Female sex 170 (43%) 61 (43%) .98
Hypertension 94 (24%) 55 (39%) .001
Smoking 43 (11%) 30 (21%) .002
Diabetes 30 (8%) 49 (35%) .001
Renal disease 26 (7%) 26 (18%) .001
Lung disease 33 (8%) 31 (22%) .001
Peripheral vascular 11 (3%) 17 (12%) .001
Cerebrovascular 19 (5%) 15 (11%) .015
Ejection fraction 50 (40-56) 40 (30-43) .001
NYHA class .001
I 16 (4%) 3 (2%)
II 73 (19%) 2 (1%)
III 156 (40%) 35 (25%)
IV 149 (38%) 101 (72%)
Coronary disease 63 (16%) 141 (100%) .001
Prior operation 17 (4%) 28 (20%) .001
Concurrent CAB 63 (16%) 123 (87%) .001
Institution Duke 307 (78%) 110 (78%) .99
Baseline characteristics of the NMR versus IMR groups are shown. Values
shown in parentheses are 25th-75th percentiles for continuous variables.
NMR, Nonischemic mitral regurgitation; IMR, ischemic mitral regurgitation;
NYHA, New York Heart Association; Prior operation, previous cardiac
operation; CAB, coronary artery bypass.versus patients with NMR (25th, 50th, and 75th percentiles:
862 The Journal of Thoracic and Cardiovascular Surgery ● Apri24, 26, and 26 mm for IMR vs 26, 30, and 34 mm for NMR;
P  .0001). Patients undergoing valve repair for IMR had
greater age, higher comorbidity (hypertension, smoking,
diabetes, renal insufficiency, lung disease, cerebrovascular
disease, and peripheral vascular disease), lower EF, higher
NYHA class, more CD, and a higher incidence of reopera-
tion compared with patients undergoing valve repair for
NMR (Table 1). No differences were observed in terms of
sex or institution. Patients with IMR were more likely to
undergo concurrent coronary bypass grafting (87% vs
16%). Severe left ventricular dysfunction (EF  0.35) oc-
curred in 9% (36/394) of patients with NMR but was
observed in 37% (52/141) of patients with IMR (P 
.0001). In the total population 31% were older than 70
years, and 7% were older than 80 years. Five patients had
moderate-to-severe MR on preoperative or prebypass echo-
cardiography, and the remaining 530 patients had severe
MR. Class III and IV congestive heart failure or anginal
symptoms were present preoperatively in 82% (441/535) of
patients. Patients from the 2 different institutions had sim-
ilar baseline characteristics, except that patients at Duke had
more hypertension, smoking, diabetes, and vascular disease
and had greater EF.
On postbypass transesophageal echocardiography, only 1
patient with IMR had more than mild MR after repair
compared with 2 patients with NMR (P  not significant).
Unadjusted 30-day mortality was higher for patients with
IMR (6/141 [4.3%]) versus those with NMR (5/394 [1.3%],
P  .04). Unadjusted operative mortality was also higher
for patients with IMR (9/141 [6.4%]) versus patients with
NMR (5/394 [1.3%], P  .01). Causes of operative death
for patients with IMR included ventricular arrhythmias in 3,
sepsis in 2, respiratory failure in 2, mediastinitis in 1,
pneumonia in 1, and low cardiac output in 1. For patients
with NMR, death was caused by heparin-induced thrombo-
sis in 1, sepsis in 1, stroke in 1, and liver failure in 1.
Postoperative complications tended to be higher in patients
with IMR (no. [%] with IMR vs no. [%] with NMR): stroke
in 3 [2.1%] vs 5 [1.3%], renal failure in 10 [7.1%] vs 9
[2.3%], prolonged ventilation [48 hours] in 8 [5.7%] vs 12
[3.0%], reoperation for bleeding in 3 [2.1%] vs 13 [3.3%],
deep sternal infection in 1 [0.7%] vs 0 [0%], sepsis in 2
[1.4%] vs 1 [0.3%], gastrointestinal complications in 8
[5.7%] vs 13 [3.3%], and new pacemaker in 6 [4.3%] vs 7
[1.8%]). Median (25th-75th) postoperative stay was 8 days
(6-11 days) for IMR and 6 days (5-8 days) for NMR (P 
.001, Mann-Whitney test).
The results of locally available late postoperative echo-
cardiograms were obtained in 58% (309/535) of patients
(85/141 [60%] with IMR and 224/394 [57%] with NMR, P
 .5). Late echocardiograms were not available in the
remainder primarily because of absence of symptoms and
murmurs. The median time (25th-75th) to last follow-up
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CDechocardiogram was 1.4 years (0.1-3.1 years) for patients
with IMR versus 1.8 years (0.3-4.3 years) for patients with
NMR. Moderate or severe MR was documented to have
recurred in 8% (30/394) of the NMR group and 11% (15/
141) of the IMR group over 9 years of follow-up. Consid-
ering only the patients with recurrent moderate or severe
MR, preoperative or late EF was less than 0.40 in 93%
(14/15) of patients with IMR and 47% (14/30) of patients
with NMR (P  .007). Three (2.1%) patients with IMR
underwent late reoperation: 1 for ring dehiscence, 1 for
inflammatory mitral stenosis, and 1 for chordal tethering
from left ventricular aneurysm. No other patients had clin-
ically apparent mitral stenosis. Twelve (3.0%) patients with
NMR underwent late reoperation: 4 for endocarditis (occur-
rence rate of 0.2%/patient-year), 1 for hypertrophic outflow
tract obstruction, 2 for late rupture of native chords, 1 for
late rupture of polytetrafluoroethylene artificial chords, 1 for
pannus ingrowth, 2 for heart transplantation for cardiomy-
opathy, and 1 for papillary muscle elongation.
A total of 93 deaths occurred over the 9 years of follow-
up. Unadjusted 5-year mortality was worse for IMR (44%
vs 16%, P  .001; Figure 1, A). In the univariable Cox
model IMR was a significant predictor of long-term mor-
tality, as were advanced age, most preoperative comorbidi-
ties, lower EF, higher NYHA class, CD, and reoperation
(Table 2). However, in the full multivariable Cox model,
only the number of preoperative comorbidities and ad-
Figure 1. Survival of patients undergoing mitral valve repair with
IMR versus NMR (No IMR) before (A) and after (B) adjustment for
differences in baseline patient characteristics.vanced age were significant independent predictors of sur-
The Journal of Thoracivival (P  .0001). IMR, sex, EF, NYHA class, CD, prior
operation, institution, and year of operation did not prove to
be significant (all P  .23) (Table III).
When individual comorbidities were examined instead of
the number of comorbidities, the only significant multiva-
riable predictors of survival were advanced age, diabetes,
renal disease, and lung disease (all P .012), whereas IMR
was not a predictor of survival (P  .4). By using propen-
sity score analysis to stratify patients into 5 strata of high
TABLE 2. Univariable Cox model predictors of survival





Age 23.60 .0001 1.04 1.02-1.06
Female sex 0.00 .93 1.02 0.68-1.53
Hypertension 3.18 .07 1.48 0.96-2.26
Smoking 0.10 .75 0.90 0.48-1.70
Diabetes 17.30 .0001 2.73 1.76-4.24
Renal 27.60 .0001 4.14 2.60-6.60
Lung 15.90 .0001 2.82 1.77-4.49
Peripheral vascular 7.53 .006 2.51 1.30-4.83
Cerebrovascular 4.37 .037 2.09 1.05-4.17
EF 20.20 .0001 0.96 0.95-0.98
NYHA class 15.20 .0005 1.77 1.28-2.43
CD 24.80 .0001 2.85 1.87-4.37
Prior operation 3.35 .05 1.79 1.00-3.22
Year of operation 0.00 .97 1.00 0.90-1.11
IMR 30.80 .0001 3.22 2.14-4.84
Institution 0.05 .83 1.05 0.66-1.69
Results of univariable Cox model analysis are shown. Age was tested by
5-year increments. HR, Hazard ratio; CL, confidence limit; EF, ejection
fraction; NYHA, New York Heart Association; CD, coronary disease; Prior
operation, previous cardiac operation; IMR, ischemic mitral regurgitation
versus nonischemic mitral regurgitation.
TABLE 3. Multivariable Cox model predictors of survival





No. of comorbidities 30.29 .0001 1.62 1.37-1.93
Age 16.78 .0001 1.29 1.14-1.46
Institution 1.50 .19 1.45 0.83-2.54
EF 1.43 .23 0.99 0.97-1.01
NYHA class 1.08 .30 1.21 0.85-1.73
IMR 0.97 .33 1.45 0.69-3.01
Female sex 0.69 .41 0.83 0.54-1.28
Prior operation 0.57 .45 1.27 0.69-2.34
CD 0.06 .81 0.91 0.43-1.93
Year of operation 0.00 .96 1.00 0.89-1.12
Results of multivariable Cox model analysis are shown. Age was tested by
5-year increments. HR, Hazard ratio; CL, confidence limit; EF, ejection
fraction; NYHA, New York Heart Association; IMR, ischemic mitral regur-
gitation versus nonischemic mitral regurgitation; Prior operation, previous
cardiac operation; CD, coronary disease.versus low propensity for IMR, IMR versus NMR also
c and Cardiovascular Surgery ● Volume 129, Number 4 863
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CDfailed to be a significant predictor either in the univariable
or multivariable setting (P  .1, Figure 2).
Cox model analysis was repeated, examining only those
patients with CD (Figure 3), and the raw unadjusted survival
was worse for patients with IMR (5-year survival, 56% 
5% for patients with IMR versus 79%  7% for patients
with NMR; P  .01). However, by means of multivariable
Cox modeling analysis, only age and number of comorbidi-
ties were significant independent predictors of survival (for
patients with IMR, odds ratio  1.7 (0.9-3.5); P  .12).
When survival of patients with IMR versus patients with
NMR was adjusted for differences in the other 8 preopera-
tive patient variables (age, sex, number of comorbidities,
EF, NYHA class, CD, prior cardiac operation, and year of
operation), long-term survival was not statistically different
between the IMR and NMR group (P  .33; Figure 1, B).
Specifically, the adjusted 5-year survival for patients with
IMR (72%) closely approximated the 5-year survival for
patients with NMR (80%). When CD and EF were com-
bined in the model, their combined 2 value was 1.527 (P
.466), and comorbidities and age were still the only predic-
tors of long-term mortality (P  .0001). When CD and EF
were omitted (7-variable model), preoperative comorbidity
and age were still the only predictors (P  .0001), and
although the IMR variable contained more prognostic in-
formation (2  3.133), it still was statistically insignificant
(P  .077).
Discussion
Most previous studies have compared long-term outcomes
after surgical treatment of IMR versus NMR with univari-
able analyses. Bouchard and associates3 found that 5-year
survival after mitral replacement was 70% for patients with
IMR versus 80% for patients with NMR. In patients under-
going combined mitral and coronary surgery, Seipeli and
coworkers21 demonstrated worse survival in patients with
Figure 2. Comparison of survival with IMR versus NMR by using
stratification for propensity score. *Less than 10 patients in quin-
tile.IMR than in patients with NMR (70% vs 85% at 5 years).
864 The Journal of Thoracic and Cardiovascular Surgery ● ApriWithout direct comparison, Gillinov and associates2,7 re-
ported 2 series from the same institution, with 5-year sur-
vival after mitral repair or replacement for IMR being 55%
versus 76% for degenerative disease. In general, no prior
study has attempted to differentiate IMR from other risk
factors as independent determinants of postoperative out-
come.
Previous hypotheses to explain the worse prognosis of
IMR include more recurrent MR after repair of IMR,12,22
more significant underlying ventricular-subvalvular pathol-
ogy, creation of mitral stenosis by undersized rings,9 in-
creased comorbidity,23 and a nebulous concept of ventric-
ular remodeling.24 The question addressed by this article is
whether the adverse outcome after repair of IMR is due to
unique differences in ischemic versus nonischemic cause or
whether the higher mortality is simply a reflection of worse
preoperative risk factors. The multivariable Cox model
analysis suggests that the lower raw survival values after
repair for IMR likely can be explained by higher preoper-
ative risk factors alone, without impugning specific mitral
or ventricular derangements.
Several technical factors might be important in produc-
ing less negative effect of IMR in the present series. First,
rigid annuloplasty rings that fix mitral annular shape in
addition to circumference were used in 95% of patients with
IMR. Previous series have included patients receiving ring-
less repairs,12 incomplete rings,25 and flexible rings, all of
whom might experience more recurrent MR.24 It is now
Figure 3. Survival of patients undergoing mitral valve repair with
CD. IMR is compared with NMR (No IMR) before (A) and after (B)
adjustment for differences in baseline patient characteristics.clear that reduction in the anterior to posterior mitral di-
l 2005
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CDmension is of critical importance in repair of IMR.26 Not
only will a rigid ring allow a larger valve area at a given
anterior-posterior dimension, but fixing annular shape in-
creases the surface area of leaflet coaptation (potentially
compensating for early or late abnormalities in submitral
geometry and providing an increased margin of safety).
Undersizing the ring in patients with ventricular dilation or
Carpentier type IIIb systolic leaflet restriction-tethering will
have a similar effect of reducing mitral anterior-posterior
annular diameter.9 Recurrent MR and reoperation rates in
the present study were low and approximated those ob-
served for NMR, emphasizing the effectiveness of rigid
rings. On the basis of these data, one might hypothesize that
routine rigid ring annuloplasty is the primary procedure of
choice for moderate-to-severe IMR.
Also of importance are other considerations, such as
reduced operative mortality caused by better postoperative
pulmonary, renal, gastrointestinal, nutritional, antibiotic,
and arrhythmia management. Reduction in acute mortality
for repair of IMR to well under 10% in this and other
series27 might influence the risk factor analysis so that only
preoperative comorbidity and age emerge as significant
determinants of long-term outcome. Severe left ventricular
dysfunction diminishes as a risk factor, perhaps because of
maintenance of ventricular-valvular continuity28 and opti-
mization of early left ventricular function. Repair also pro-
vides the best chance for ventricular recovery from volume
overload29 in addition to reversal of ischemic dysfunction
after CAB.30 Just as interesting, CD does not seem to be a
long-term risk factor, perhaps reflecting the beneficial ef-
fects of coronary revascularization.
This study has several limitations. First, one cannot ex-
clude the possibility that IMR has some subtle negative
effect on survival not detected in this relatively small sam-
ple of 535 patients.
Second, the observational nature of this study could have
produced biases by not adequately accounting for inherent
differences between the IMR and NMR groups and con-
founding institutional effects. Some inherent degree of co-
linearity of independent variables and inability to guarantee
a complete list of independent variables are limitations of
this and any retrospective analysis of complex and interre-
lated variables.
Third, the hypothesis tested might seem like a tautology
in that IMR can be defined by using risk factors of EF and
CD. In fact, however, this series included 20 patients with
NMR with left ventricular dysfunction and CD, thus em-
phasizing that patients with IMR were only a subset of all
patients with CD and impaired EF. Offsetting that limita-
tion, when the analysis was performed without CD and EF,
IMR remained an insignificant determinant of long-term
survival relative to preoperative comorbidities and age.
The Journal of ThoraciDelayed or deferred referral of patients with IMR versus
NMR for mitral repair purely on the basis of mitral disease
cause is not supported by these data. Reluctance to refer
patients with IMR for repair was evidenced in this study by
the fact that patients with IMR with NYHA class I or II
symptoms were rarely referred for surgical intervention
(NYHA class I-II symptoms in 4% (5/141) of IMR referrals
vs 23% (89/394) of NMR referrals, P .0001). We strongly
acknowledge that IMR and NMR are not the same; by
definition, they are different. Here we present data that raise
the concern that reluctance to refer patients with IMR for
repair on the basis of the cause of valve damage alone is
unwarranted and might deprive patients with IMR of poten-
tially beneficial therapy.
In conclusion, with routine application of modern surgi-
cal techniques for mitral repair, IMR does not seem to be an
independent predictor of long-term outcome after adjusting
for age, preexisting comorbidities, and clinical findings.
Future surgical risk assessment and therapeutic decision
making should be based on overall patient condition and not
be biased by ischemic cause of MR. It is notable that
aggressive valve repair in IMR resulted in an adjusted
survival that was similar to that in cases of NMR. Irrespec-
tive of whether this statistical result is unique to this series
or can be reproduced in the future, it does indicate that
outcomes have improved dramatically in the IMR subgroup
with routine application of rigid ring annuloplasty.
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Discussion
Dr David Adams (New York, NY). Don, congratulations to you
and Scott and the coauthors of this study. Your observation that
comorbidities are at least as important and perhaps even more
important than the presence of IMR in determining survival in
patients undergoing mitral repair might have important implica-
866 The Journal of Thoracic and Cardiovascular Surgery ● Apritions for future guidelines regarding intervention in this complex
patient population. I would like to emphasize that this is a unique
study in that it represents one of the first and largest series of
patients with moderate or severe IMR treated uniformly with
downsized remodeling (ie, rigid or semirigid annuloplasty ring)
with at least midterm follow-up. I have a few questions.
I wonder whether you could just clarify again recurrent MR in
your study. When did it happen? How common was it?
Dr Glower. Again, we do not have complete information in
that many of our patients came from a long distance away, and we
do not have any echocardiographic follow-up data on them. There-
fore, there is some potential bias there, but I think it is a fairly
random bias. And in the 58% of patients in whom we did have
echocardiographic data regarding recurrent regurgitation, as you
saw in one graph, it tended not to recur immediately. It tended to
recur either months or a few years out. And it is not surprising (but
it was certainly statistically significant) that the patients who
tended to get the recurrent regurgitation were those who had the
lower EF preoperatively and especially those who were left with a
low late EF. Not surprisingly, those are the ones who had late
regurgitation.
Dr Adams. A few years ago Lishan Aklog presented the
Brigham experience with mitral repair and IMR to this association,
noting that patients with residual MR of greater than 2 after
repair had poorer survival compared with patients with lesser
degrees of MR after repair. What was the significance of residual
or recurrent MR in your study in terms of survival?
Dr Glower. That is a very good question. We actually have not
looked at that yet to see whether there was association between late
survival and those patients who did have late regurgitation. I
suspect the answer would be that there is an association. This is
because we know that those who had late regurgitation had lower
EF, and certainly lower EF is associated with poorer survival.
Therefore, I suspect the answer will be true, but we have not
looked at that specifically.
Dr Adams. In your manuscript you noted a 7% operative
mortality and a 4% 30-day mortality, which is quite good in the
ischemic group, especially considering the study began in 1993
and 20% of your patients in the ischemic group were in fact
undergoing reoperation. I wonder whether you can just tell us
briefly about any strategies you have used to get those kinds of
results?
Also, just comment on the inclusion of patients with single-
vessel disease in this series. Do you think that biased the results in
any way? Is it possible that any of these patients snuck in with
degenerative disease, or, let’s say, type 1 annular dilatation that
was not related to pure ischemia because you included single-
vessel disease?
Dr Glower. I think there is always the possibility of having
some patients without an ischemic cause in here. But we went
through these patients pretty carefully, and we pretty strictly fol-
lowed the criterion of actually not only having impaired EF but
also having a regional wall motion abnormality that was appropri-
ate for the coronary lesion. Therefore, I think our series is pretty
clean in that regard.
In terms of how many patients had single-vessel disease, it is
not very many; I do not have the exact numbers. It is a relatively
low number. A high percentage of these subjects had multivessel
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better than we are used to seeing in the literature. I think there are
several factors here.
For one, this is clearly a more recent series than many of the
series that are out there that extend back into an earlier era. We
were fairly fortunate in being relatively early to downsize the ring
in ischemic patients. I think many groups are coming to that
realization only recently. I think we were just lucky to have done
that at an earlier point in time, and I think that has been fairly
important. Among other things, I think anesthesia obviously has
improved, and there are even other more subtle things.
For example, there are a lot of redo patients in this series. In our
hands the operative mortality for a redo sternotomy for IMR is at
least 14% to 15%. In this series there were a significant number of
patients who actually had a small port-access thoracotomy for
isolated IMR, and we know from our own recent experience the
mortality on that is probably only about 1%. Therefore, there are
several things we know now and have incorporated into this series
that probably have contributed to the mortality being lower than
we might have traditionally thought for IMR.
Dr Adams. It is the biggest series I am aware of, with 24 and
26 rigid or semirigid rings, and therefore obviously this is a group
that is worth continuing to follow. My last question is about EF
and NYHA class. You did not find that either independently
predicted survival in your study after mitral repair, which is in
direct contrast to many studies in the literature. Can you clarify this
for us further?
Dr Glower. That is a good question. Even though this is a
relatively large series with more than 500 patients, we only had 90
deaths to look at statistically, and there are many factors that we
would all suspect have to be predictors of mortality that did not
come out as significant in this series, including EF and NYHA
classification. I think part of that just might be a statistical power
problem.
However, on the basis of earlier series, we would have ex-
pected that EF would have been much stronger, maybe one of the
top 2 or 3 items, along with age or maybe redo operations, and it
did not come out this way. And I can only speculate that perhaps
the early and aggressive use of undersized rings might have
protected us from some of that late mortality, if indeed the later
deaths are related to recurrence.
Dr Bruce W. Lytle (Cleveland, Ohio). In your conclusion you
implied that this is going to help you in terms of selection. I mean,
if I could paraphrase the results of the study, what it shows is that
if only these patients with ischemic heart disease or ischemic
mitral insufficiency were not old, did not have comorbidities, and
did not have coronary artery disease, they do really well, but they
do, and so how has this helped you in terms of patient selection?
Dr Glower. I think it is more of a bias, perhaps more on the
part of the cardiologists than on the part of surgeons, and I am sure
that you see it also. There are quite a few patients out there with
IMR of at least a moderate-to-severe degree who the cardiologist
believes will never tolerate an operation. Whereas when a similar
patient, 85 years old, might even have CD and mitral valve
prolapse, they think this is obviously something they can repair
and has much lower mortality. Therefore, the second patient gets
referred. It is a fairly subtle concept, and it should not be too
The Journal of Thoracisurprising. Yet I think there really is a lot of thinking along that
line that might be inappropriate.
Dr Richard J. Shemin (Boston, Mass). I think one of the
unique aspects of this study is that more than 500 patients were
operated on by only 2 surgeons; therefore, you get a lot of
operative consistency. Can you share with us the surgeon’s phi-
losophy on downsizing? Do you always use the smallest ring on
the shelf, or do you downsize 2 sizes? I think these technical
aspects would be of interest. It is somewhat unusual to see the use
of pledget-supported mattress sutures used in some of the valve
repairs. I am interested in your indications and when you used
pledget-supported sutures. Aggressive downsizing of a very larger
annulus can lead to dehiscence of a ring. Did you experience this
complication, resulting in a change in technique by using a
pledget-supported mattress suture instead of the more common
nonpledget-supported mattress suture technique?
Dr Glower. I think our series includes both pledget-supported
sutures and nonpledget-supported sutures. I think you will find
among persons here in the audience a pretty good mix of who does
what. In my own practice I originally did not use pledget-sup-
ported sutures at all until I got 2 dehiscences, and I think it is
important to look at those 2 patients with recurrent regurgitation.
One of them was someone who had a previous sternotomy,
previous coronary bypass grafting. As best I could tell, he came to
me with IMR and what I thought was about a 45-mm annulus, and
I put a 26-mm ring in him. He did great for about a month, and
then the ring dehisced. Therefore, I took him back. I did a suture
annuloplasty first. I put pledget-supported sutures in him, put a
26-mm ring back in, and he did fine. Therefore, what I have tended
to do in the patients who have really massive dilation (particularly
in a redo setting in which the redo mediastinum might pull the
ventricle open) is to be a little bit more aggressive when placing
pledget-supported sutures.
On the other hand, I do not do it routinely because sometimes
I get a little bit more distortion of the valve leaflets with pledgets
than otherwise. Therefore, I do not think there is a right or wrong
there, unless you really have a lot of tension on a significantly
dilated annulus. Then you should be aware and maybe think about
pledget-supported sutures.
I think you are right that the consistency here with 2 surgeons
and a relatively high volume might help a bit. We have had similar
philosophies. Our sizing philosophy has been very simple. Obvi-
ously any patients who had prolapse or Barlow disease or big
valves to begin with were not considered ischemic in this series.
We put them in a nonischemic category, even though they might
have had an infarction and even though they might have had
dilation. Ischemic patients all had normal-sized valves. We would
size the anterior leaflet and the distance between the commissures
and then go down by 2 sizes. That pretty much routinely led us to
24 and 26 mm. We did not go to any fixed size. We would try to
match it to the patient, and this is pretty much what we found.
Another question along those lines might be as follows: Is there
something important about the fact that you chose complete rings
or the fact that you chose rigid or semirigid rings? I do not know.
We do not really have any data in our experience to compare
complete with partial rings or rigid with semirigid rings to be able
to answer that. I think the next article might be interesting in that
c and Cardiovascular Surgery ● Volume 129, Number 4 867
Surgery for Acquired Cardiovascular Disease Glower et al
A
CDregard. Our decision was primarily based on the advice and think-
ing of Carpentier, who got us going on this.
There also are some data from Dr Miller recently leading us to868 The Journal of Thoracic and Cardiovascular Surgery ● Apriseptal–free wall distance, which a rigid ring might do better than
a flexible ring. But we cannot really directly support that. We can
just say that, taking the philosophy that we did take, the resultsthink that there might be some advantages to maintaining the were good and consistent.l 2005
